NeuroSense to Present Clinical and Biomarker Evidence at NEALS 2026
The presentation will highlight how findings from the PARADIGM program are informing PrimeC's Phase 3 development.
Related stories
South Korea’s Kospi Opens 3.0% Lower at 5760.35
M impact | EQUITY | Oct 30, 2026, 12:01 AM UTC
Nikkei Opens 0.5% Lower at 64,344.37
The Nikkei Stock Average opened 0.5% lower, dragged by electronics and metals stocks.
M impact | EQUITY | Oct 30, 2026, 12:01 AM UTC
SK Hynix shares fall 5%
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
US stock futures decline
L impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
Origin Energy Q1 APLNG Revenue Jumps on Higher Prices and Data Centre Demand
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC
Seatrium Secures FPSO Integration Contract Worth Over S$200 Million
Seatrium secured an FPSO integration contract valued at over S$200 million from SBM Offshore.
M impact | EQUITY | Oct 30, 2026, 12:00 AM UTC